Immunovant, Inc.IMVTNASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+18.1%
5Y CAGR+14.9%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+18.1%/yr
vs +1709.4%/yr prior
5Y CAGR
+14.9%/yr
Recent acceleration
Acceleration
-1691.3pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2x
Strong expansion
Streak
3 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$79.15M+2.5%
2025$77.23M+34.8%
2024$57.28M+19.3%
2023$48.02M-11.4%
2022$54.23M+37.2%
2021$39.51M+236.9%
2020$11.73M+2618203.6%
2019$448.00-100.0%
2018$1.48M-